Company history

Takeda began in June 1781, when the first Takeda Chobei took over a guild share on Dosho-machi, the Osaka street where medicine dealers traded on mutual credit, and set up as a wholesaler broking Chinese and Japanese herbal drugs to the apothecaries. On Dosho-machi trust was the whole business, and it could only be built over years of dealing; the family’s custom of passing the name “Takeda Chobei” down the generations was a device for handing that time-earned credit — the shop’s standing, not a single man’s — to the next head. In 1871 the house added the importing of Western medicines, laying a second trade over the first and acquiring, early, a habit it would never lose: when the environment shifted, abandon the old model and move upstream.

The decisive shift came with the First World War. High prices and counterfeits had already pushed Takeda to make some of its own drugs — its first dedicated factory dates to 1895 — but when the war cut off imports from Germany in 1914, the whole import-dependent structure gave way. In 1915 Takeda opened its own works in Osaka and turned, in earnest, from a firm that moved medicines into one that made them. Around this pivot it built the apparatus of a research-driven maker: a test-and-research department in 1908 (the seed of its laboratories), incorporation as Takeda Chobei Shoten in 1925, and, over the late 1930s, the domestic synthesis of vitamins C, B1 and K.

In August 1943 the firm took its present name, Takeda Pharmaceutical. The war years and the chaos that followed were anything but smooth, but Takeda came through with its plant intact — and used it well. Making vitamin and glucose preparations from whatever raw materials it could get and supplying them to the public through legitimate channels rather than the black market did as much for its reputation as any product had, and set the base for the new-drug work of the postwar decades.

In March 1954 Takeda launched Alinamin, an over-the-counter tonic built on a vitamin-B1 derivative, into a malnourished postwar Japan. Advertising fronted by the film star Toshiro Mifune and a nationwide single-price system run through the “Takeda-kai” dealer network gave Takeda both a household name and control of its own distribution; by fiscal 1955 vitamin products were 37% of sales. Takeda was now a company that not only made drugs but sold them — and the mass-market model threw off cash and fame in equal measure.

It also carried a cost that would take years to surface. Leaning on a single blockbuster consumer product slowed Takeda’s investment in the prescription drugs that were becoming the industry’s real frontier; when the medicine boom broke in 1964, demand stalled and the dependence on one product bit straight into earnings. The success of Alinamin shaped Takeda’s thinking for a generation.

The same decades brought the counter-lesson. Takeda had begun selling a clioquinol preparation in 1959, and in the 1970s the SMON drug-injury scandal surfaced as a national issue. From 1977 to 1980 Takeda booked provisions totalling some $87M (¥20bn), choosing to absorb the near-term hit in order to fix the liability, shrink the uncertainty of future compensation and clear the ground for the research spending the next era would demand — spending the mass-market cash pile now made possible.

A 1976 substance-patent regime gave discovery patents real force, and Takeda pushed its R&D budget to roughly double its rivals’. Kunio Takeda, then posted to the U.S. subsidiary, concentrated resources on the prostate-cancer drug Leuprin, launched in America in 1989; its infrequent dosing won over clinicians and it grew into a mainstay earning more than $724.7M (¥100bn) worldwide. Yet nobody had aimed at a ¥100-billion drug from the start — at launch even the development director called the market “not, unfortunately, a large one” — and much of the win rested on judgment in the field and on luck. The habit of marketing it in the United States by Takeda’s own hand left inside the company the clinical and commercial base that later acquisitions would build on.

When Kunio Takeda took the presidency in 1993, he turned a diversified conglomerate back into a drug company. A 1995 plan cut 3,500 jobs toward a 7,500-person workforce, and from 2005 Takeda hived off urethane, vitamins, agrochemicals, food and life-environment businesses one by one. “We either somehow survive as a local company, or we vanish,” he said in 1996 — a blunt statement of why focus was not optional. It was the end of the long postwar diversification, and the shedding of weight Takeda needed to live on drugs alone.

Focus then exposed a thin pipeline. Under president Yasuchika Hasegawa, Takeda bought the North American cancer-discovery house Millennium for about $8.9 billion in 2008 — the start of a “buy time” strategy — and in 2011 acquired Nycomed for some $13.8B (¥1.1tn), taking Europe and the emerging markets in a single stroke. Paid for in cash, the deals avoided dilution but ended Takeda’s debt-free era and opened the door to leverage. Behind them lay the problem they were meant to solve: over the nine and a half years to late 2012, Takeda had spent roughly $30.1B (¥2.4tn) on R&D without producing a blockbuster to rival Actos. Unable to grow enough managers to run what it had bought, in 2015 it installed a foreign chief executive, Christophe Weber from GlaxoSmithKline — global logic and the admission of a succession it had not cultivated at home.

Weber kept building by purchase — ARIAD for $5.2B (¥583bn) in 2017 to reinforce rare disease, a global headquarters opened in Tokyo in 2018 alongside the registered Osaka head office, and a New York ADR listing that December — and then made the whole strategy’s capstone bet. In January 2019 Takeda acquired Shire for roughly $62 billion, vaulting into the world’s top ten: it took a rare-disease and plasma-derived business in one move, and revenue leapt from about $18.1B (¥2tn) to past $27.5B (¥3tn). It was among the largest overseas acquisitions ever made by a Japanese company — the summing-up of the focus-then-expand strategy, and a wager pushed to the edge of Takeda’s financial capacity.

Recovering the premium took longer than planned, and interest-bearing debt swelled to about $89.9B (¥9.8tn). Weber cast Takeda, a 240-year-old house, as a company to be judged over the long term, and justified the investment on that horizon; but with goodwill charges running on, the case for a ¥6-trillion-plus outlay could only be settled by clinical results years out, and the ratings faced downgrade pressure from the day the deal closed. From then on Takeda had to carry two outflows at once — repaying the acquisition debt and funding the research that would produce the next mainstay — and reconciling the two became the axis of how it was run. By fiscal 2026 the debt had been brought back toward $28.5B (¥4.5tn).

To rebuild the balance sheet, Takeda sold Wako Pure Chemical to Fujifilm in 2017 and, in August 2020, let go of the Alinamin over-the-counter business for about $2.3B (¥242bn) to a U.S. fund — cutting loose the flagship it had sold since 1954 and closing the seventy-year model of earning cash from consumer drugs. Takeda was now, in name and in fact, a prescription-only company: a family firm that had carried a name and its credit down from an eighteenth-century drug dealer had become a foreign-led global drugmaker. In June 2026 Julie Kim succeeded Weber as CEO — the first leadership change in eleven years — inheriting a company that must now prove it can raise its next flagship in-house, launching FRUZAQLA and the dengue vaccine QDENGA from the pipeline it assembled by acquisition, all while a progressive dividend keeps shareholders on board.